Navigation Links
AEterna Zentaris Announces Results from its European Phase 3 Study with Cetrorelix in Benign Prostatic Hyperplasia
Date:12/7/2009

QUEBEC CITY, Dec. 7 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS; TSX: AEZ) (the "Company"), a global biopharmaceutical company focused on endocrine therapy and oncology, today reported Phase 3 results for its European efficacy trial Z-036 in benign prostatic hyperplasia (BPH), with cetrorelix pamoate.

Study Z-036 did not reach its primary endpoint. There were no clear differences in overall efficacy, with all 3 groups (including placebo) showing an improvement in International Prostate Symptom Score (IPSS) of approximately 6 points that was maintained throughout the 52 weeks. There was observation of an improvement in uroflow, both maximum and mean, and in residual volume in all treatment groups. These favorable changes are reflected in an overall improvement in Quality of Life measures. Cetrorelix was well tolerated, there were no relevant differences to placebo with regard to both clinical adverse events or changes in laboratory parameters with the exception of the anticipated hormonal changes.

Juergen Engel, Ph.D., AEterna Zentaris President and CEO stated, "We are obviously disappointed by the failure of study Z-036 to reach its efficacy endpoint. Despite the disappointment, we would like to thank the investigators and all those involved in this project for their dedicated work. We will now focus our development efforts on our late-stage oncology compounds perifosine, our oral PI3K/AKT inhibitor and AEZS-108, our targeted doxorubicin conjugate, as well as our oral ghrelin agonist AEZS-130 in endocrinology."

About study Z-036

The multi-center efficacy trial Z-036 was conducted in 39 sites in 10 European countries, under the supervision of lead investigator, Prof. Frans MJ Debruyne, M.D., Director of the Andros Mannenkliniek in Arnhem, The Netherlands. Patients entered a 1- to 4
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
2. AEterna Zentaris to Present at Upcoming UBS Global Life Sciences Conference in New York
3. AEterna Zentaris Announces Outcome of Managements Strategic Review
4. AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment
5. AEterna Zentaris Reports First Patients Treated with Anti-Cancer Compound AEZS-108 in Phase 2 Trial in Ovarian and Endometrial Cancers
6. AEterna Zentaris to Present at the Upcoming Roth Capital Partners 20th Annual OC Growth Stock Conference in Dana Point, California
7. Aeterna Zentaris to Announce Fourth Quarter and Full-Year 2007 Financial and Operating Results on March 5, 2008
8. AEterna Zentaris Announces the Departure of SVP, Administrative and Legal Affairs
9. AEterna Zentaris and Paladin Labs Announce Sale and Purchase of Miltefosine Rights
10. Aeterna Zentaris Reports Fourth Quarter and Full-Year 2007 Financial and Operating Results
11. Aeterna Zentaris Begins Second Phase 3 Trial of Cetrorelix for Benign Prostatic Hyperplasia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/17/2013)... Z Trim Holdings, Inc. (OTC Markets: ... ingredients to a variety of industries, today announced ... application at this year,s annual Institute of Food ... , July 13-16. The Company will demonstrate how ... in meat products thereby helping manufacturers lower costs ...
(Date:6/17/2013)... , June 17, 2013 ... ) has announced the addition of the ... - by Formulations [Liposomes, Microspheres, & Nanoparticles], ... Pen, Needle Free & Auto Injectors] & ... their offering. ,      (Logo: ...
(Date:6/17/2013)... As interest increases in developing novel biomarker ... the need to keep up with the pace of ... the first in a series titled “Better Methods for ... a range of technologies, introduces a novel method for ... proteins than either ELISA or traditional LCMS can achieve. ...
(Date:6/17/2013)... VARTA Microbattery, the ... the opening of its new North American Headquarters ... business community received an inside look at the ... powered the camera Neil Armstrong used to capture ... showcasing VARTA’s many historic achievements and innovative new ...
Breaking Biology Technology:Z Trim to Spotlight New Meat Applications at IFT 2013 in Chicago 2Z Trim to Spotlight New Meat Applications at IFT 2013 in Chicago 3North America Injectable Drug Delivery Market - by Formulations, Devices & Therapeutics- Forecasts to 2017 2North America Injectable Drug Delivery Market - by Formulations, Devices & Therapeutics- Forecasts to 2017 3Quantitative Analysis of Biomarkers, New Life Science Webinar Hosted by Xtalks 2VARTA Microbattery Celebrates New North American Headquarters in Rye, NY 2VARTA Microbattery Celebrates New North American Headquarters in Rye, NY 3VARTA Microbattery Celebrates New North American Headquarters in Rye, NY 4
... and existing investors complete a $17.3 million Series C investment ... Rosenthal, appointed as CEO , , - Aggressive launch ... , , - Expansion of management team, R&D and ... and GALWAY, Ireland, June 15 Cappella, Inc. ...
... 2009 (EurekAlert)--Advanced Cell Technology, Inc. (OTC:ACTC.PK) and its ... and efficacy of human embryonic stem cell (hESC)-derived ... suitable for human clinical trials. Two important early ... for the treatment of age-related macular degeneration and ...
... MedPredict Market Research, a global provider of pharmaceutical ... report entitled "Thought Leader Insight & Analysis: Alzheimer,s Disease," ... biotech companies with a stake in the market for ... http://www.medpredict.com/website/home.aspx ). , , ...
Cached Biology Technology:Cappella Inc. Secures $17.3 Million Series C Investment 2Cappella Inc. Secures $17.3 Million Series C Investment 3Cappella Inc. Secures $17.3 Million Series C Investment 4Cappella Inc. Secures $17.3 Million Series C Investment 5Assessment of safety and efficacy of human embryonic stem cell therapy 2Assessment of safety and efficacy of human embryonic stem cell therapy 3New MedPredict Report Reveals Top Alzheimer's Experts' Insights on Diagnostics and Treatments in Development Pipeline 2
(Date:6/17/2013)... TORONTO, June 17, 2013How kids eat their food may turn ... according to a new study out of St. Michael,s Hospital. ... family physician, found a significant association between poor eating ... of non-HDL or "bad" cholesterol, putting them at ... appeared online in the Canadian Medical Association Journal ...
(Date:6/17/2013)... Vitamin D supplementation may help delay early onset of ... results were presented Monday at The Endocrine Society,s 95th ... generally begins between the ages of 10 and 14. ... 16 years of age. Precocious puberty is diagnosed in ... 8; in boys, it is diagnosed when these changes ...
(Date:6/17/2013)... Amphibian populations are declining worldwide and a major ... by bullfrogs, but a two-year study shows they can ... bullfrogs are a tolerant carrier host that just spreads ... eggs in controlled experimental conditions, they found at least ... also called Bd or a chytrid fungus, can be ...
Breaking Biology News(10 mins):Poor eating behaviors may put preschoolers at risk for later health problems 2Vitamin D supplementation may delay precocious puberty in girls 2Bullfrogs may help spread deadly amphibian fungus, but also die from it 2
... 2010, NEW ORLEANS, LA Broncus Technologies, Inc., a ... for lung diseases, announced today at the American ... its LungPoint system version 2.1. The bronchoscopic navigation ... the meeting. These highlight the clinical benefits of ...
... WHAT: The World Science Festival launches its first full day ... event will feature a keynote address by Harold Varmus, co-chair ... as well as a live simulcast of the announcement of ... from Oslo, Norway. A panel discussion follows, moderated by ...
... CITY (May 14, 2010)--The New York Stem Cell Foundation ... the Robertson Foundation, established by Julian and Josie Robertson. ... support, will provide funding for NYSCF-Robertson Investigators in NYSCF,s ... of the NYSCF-Robertson Stem Cell Prize. This ...
Cached Biology News:LungPoint system results presented at American Thoracic Society 2010 International Conference 2LungPoint system results presented at American Thoracic Society 2010 International Conference 3
IgD Chain C (AMS 9.1)...
Bethyl Laboratories packages antibodies, conjugates and calibrators to provide quantitative ELISA kits. Each kit contains the following components, sufficient for 1000 single well assays....
Applications: Epitope mapping, Mapping protein-protein contacts, Identification of enzyme substrates/inhibitors, Identification of receptor agonists/antagonists...
Bethyl Laboratories packages antibodies, conjugates and calibrators to provide quantitative ELISA kits. Each kit contains the following components, sufficient for 1000 single well assays....
Biology Products: